{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T05:53:42Z","timestamp":1773726822191,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"15-16","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1007\/s00508-006-0644-8","type":"journal-article","created":{"date-parts":[[2006,9,6]],"date-time":"2006-09-06T08:51:54Z","timestamp":1157532714000},"page":"473-478","source":"Crossref","is-referenced-by-count":49,"title":["Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients","Osteonekrose der Kieferknochen und Bisphosphonate bei Patienten mit malignen Erkrankungen"],"prefix":"10.1007","volume":"118","author":[{"given":"Arno","family":"Wutzl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Eisenmenger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Czerny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doris","family":"Moser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Pietschmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolf","family":"Ewers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnulf","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"80","key":"644_CR1","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1652::AID-CNCR15>3.0.CO;2-Z","volume":"15","author":"MJ Rogers","year":"1997","unstructured":"Rogers MJ, Watts DJ, Russell RG (1997) Overview of bisphosphonates. Cancer 15 (80): 1652","journal-title":"Cancer"},{"issue":"99","key":"644_CR2","first-page":"462","volume":"26","author":"J Kovarik","year":"1987","unstructured":"Kovarik J, Niebauer B, Fruhwald F, Seidl G (1987) Aseptic humerus head necrosis \u2013 tortuous path of a maker of scythes through expert medicine. Wien Klin Wochenschr 26 (99): 462","journal-title":"Wien Klin Wochenschr"},{"issue":"97","key":"644_CR3","first-page":"311","volume":"29","author":"J Kovarik","year":"1985","unstructured":"Kovarik J, Niebauer B, Woloszczuk W, Fruhwald F, Kolbe H (1985) EHDP (ethylidene-1-hydroxy-1,1-diphosphonate) in the treatment of polyosseous Paget disease. Wien Klin Wochenschr 29 (97): 311","journal-title":"Wien Klin Wochenschr"},{"issue":"115","key":"644_CR4","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/BF03041028","volume":"14","author":"H Gisslinger","year":"2003","unstructured":"Gisslinger H, Kees M (2003) Therapy strategies for multiple myeloma: current status. Wien Klin Wochenschr 14 (115): 451","journal-title":"Wien Klin Wochenschr"},{"issue":"63","key":"644_CR5","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.joms.2005.01.010","volume":"5","author":"JW Hellstein","year":"2005","unstructured":"Hellstein JW, Marek CL (2005) Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg 5 (63): 682","journal-title":"J Oral Maxillofac Surg"},{"key":"644_CR6","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1097\/00000421-200212001-00006","volume":"25","author":"RE Coleman","year":"2002","unstructured":"Coleman RE (2002) Future directions in the treatment and prevention of bone metastases. Am J Clin Oncol 25: S32","journal-title":"Am J Clin Oncol"},{"issue":"334","key":"644_CR7","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","volume":"22","author":"JR Berenson","year":"1996","unstructured":"Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 22 (334): 488","journal-title":"N Engl J Med"},{"issue":"6","key":"644_CR8","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.2000.18.6.1378","volume":"18","author":"BE Hillner","year":"2000","unstructured":"Hillner BE, Ingle JN, Berenson JR, Janjan NA, Albain KS, Lipton A, et al (2000) American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol 18 (6): 1378","journal-title":"J Clin Oncol"},{"issue":"8","key":"644_CR9","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1200\/JCO.1999.17.3.846","volume":"17","author":"RL Theriault","year":"1999","unstructured":"Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF, et al (1999) Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 17 (8): 846","journal-title":"J Clin Oncol"},{"issue":"97","key":"644_CR10","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1172\/JCI118722","volume":"15","author":"GA Rodan","year":"1996","unstructured":"Rodan GA, Fleisch HA (1996) Bisphosphonates: mechanisms of action. J Clin Invest 15 (97): 2692","journal-title":"J Clin Invest"},{"issue":"6","key":"644_CR11","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1172\/JCI114100","volume":"83","author":"DE Hughes","year":"1989","unstructured":"Hughes DE, MacDonald BR, Russell RG, Gowen M (1989) Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 83 (6): 1930","journal-title":"J Clin Invest"},{"issue":"10","key":"644_CR12","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/jbmr.5650101008","volume":"10","author":"DE Hughes","year":"1995","unstructured":"Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, et al (1995) Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10 (10): 1478","journal-title":"J Bone Miner Res"},{"issue":"2","key":"644_CR13","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S8756-3282(95)00150-6","volume":"17","author":"H Murakami","year":"1995","unstructured":"Murakami H, Takahashi N, Sasaki T, Udagawa N, Tanaka S, Nakamura I, et al (1995) A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone 17 (2): 137","journal-title":"Bone"},{"issue":"4","key":"644_CR14","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2165\/00003495-200363040-00009","volume":"63","author":"K Wellington","year":"2003","unstructured":"Wellington K, Goa KL (2003) Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy. Drugs 63 (4): 417","journal-title":"Drugs"},{"issue":"10","key":"644_CR15","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1034\/j.1600-0714.2000.291006.x","volume":"29","author":"MA Gonzalez-Moles","year":"2000","unstructured":"Gonzalez-Moles MA, Bagan-Sebastian JV (2000) Alendronate-related oral mucosa ulcerations. J Oral Pathol Med 29 (10): 514","journal-title":"J Oral Pathol Med"},{"issue":"4","key":"644_CR16","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s100670050116","volume":"18","author":"N Demerjian","year":"1999","unstructured":"Demerjian N, Bolla G, Spreux A (1999) Severe oral ulcerations induced by alendronate. Clin Rheumatol 18 (4): 349","journal-title":"Clin Rheumatol"},{"issue":"9","key":"644_CR17","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","volume":"61","author":"RE Marx","year":"2003","unstructured":"Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61 (9): 1115","journal-title":"J Oral Maxillofac Surg"},{"issue":"5","key":"644_CR18","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","volume":"62","author":"SL Ruggiero","year":"2004","unstructured":"Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62 (5): 527","journal-title":"J Oral Maxillofac Surg"},{"key":"644_CR19","unstructured":"Expert panel recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaws (2004) Professional education material. Novartis, June 2004"},{"issue":"104","key":"644_CR20","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/cncr.21130","volume":"1","author":"CA Migliorati","year":"2005","unstructured":"Migliorati CA, Schubert MM, Peterson DE, Seneda LM (2005) Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone. Cancer 1 (104): 83","journal-title":"Cancer"},{"issue":"9","key":"644_CR21","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S0278-2391(03)00328-8","volume":"61","author":"J Wang","year":"2003","unstructured":"Wang J, Goodger NM, Pogrel MA (2003) Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 61 (9): 1104","journal-title":"J Oral Maxillofac Surg"},{"issue":"2","key":"644_CR22","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.joms.2003.08.009","volume":"62","author":"HK Oh","year":"2004","unstructured":"Oh HK, Chambers MS, Garden AS, Wong PF, Martin JW (2004) Risk of osteoradionecrosis after extraction of impacted third molars in irradiated head and neck cancer patients. J Oral Maxillofac Surg 62 (2): 139","journal-title":"J Oral Maxillofac Surg"},{"issue":"3","key":"644_CR23","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/hed.2890040313","volume":"4","author":"HC Schwartz","year":"1982","unstructured":"Schwartz HC (1982) Osteonecrosis of the jaws: a complication of cancer chemotherapy. Head Neck Surg 4 (3): 251","journal-title":"Head Neck Surg"},{"issue":"4","key":"644_CR24","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1754-4505.2002.tb01178.x","volume":"22","author":"EC Sung","year":"2002","unstructured":"Sung EC, Chan SM, Sakurai K, Chung E (2002) Osteonecrosis of the maxilla as a complication to chemotherapy: a case report. Spec Care Dentist 22 (4): 142","journal-title":"Spec Care Dentist"},{"issue":"6","key":"644_CR25","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0305-7372(03)00117-8","volume":"29","author":"JH Maduro","year":"2003","unstructured":"Maduro JH, Pras E, Willemse PH, de Vries EG (2003) Acute and long-term toxicity following radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancer. Cancer Treat Rev 29 (6): 471","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"644_CR26","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1053\/sarh.2002.33724b","volume":"32","author":"Y Assouline-Dayan","year":"2002","unstructured":"Assouline-Dayan Y, Chang C, Greenspan A, Shoenfeld Y, Gershwin ME (2002) Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum 32 (2): 94","journal-title":"Semin Arthritis Rheum"},{"issue":"18","key":"644_CR27","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2000.18.18.3262","volume":"15","author":"LA Mattano Jr","year":"2000","unstructured":"Mattano LA Jr, Sather HN, Trigg ME, Nachman JB (2000) Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group. J Clin Oncol 15 (18): 3262","journal-title":"J Clin Oncol"},{"issue":"349","key":"644_CR28","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1056\/NEJMoa023110","volume":"31","author":"MP Whyte","year":"2003","unstructured":"Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S (2003) Bisphosphonate-induced osteopetrosis. N Engl J Med 31 (349): 457","journal-title":"N Engl J Med"},{"issue":"349","key":"644_CR29","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMp038103","volume":"31","author":"JC Marini","year":"2003","unstructured":"Marini JC (2003) Do bisphosphonates make children's bones better or brittle? N Engl J Med 31 (349): 423","journal-title":"N Engl J Med"},{"issue":"34","key":"644_CR30","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","volume":"23","author":"A Bamias","year":"2005","unstructured":"Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors? J Clin Oncol 23 (34): 8580","journal-title":"J Clin Oncol"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-006-0644-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00508-006-0644-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-006-0644-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T21:53:14Z","timestamp":1559080394000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00508-006-0644-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":30,"journal-issue":{"issue":"15-16","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["644"],"URL":"https:\/\/doi.org\/10.1007\/s00508-006-0644-8","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8]]}}}